经导管心脏瓣膜新窦内叶瓣血栓形成的流体力学
研究基于RESOLVE研究中的CoreValve、Evolut R和SAPIEN 3的TAVR患者术后4D CT数据,排除抗凝患者,分析瓣膜部署几何与血栓体积。发现SAPIEN 3瓣叶血栓者瓣膜直径扩张更大,CoreValve/Evolut R血栓体积随植入深度线性增加,体外模型显示瓣上部署可减少停滞区。提示部署几何影响血栓风险。
要点
- SAPIEN 3瓣叶血栓者平均直径扩张比无血栓者大10%。
- CoreValve/Evolut R血栓体积随植入深度线性增加(R²=0.7)。
- 瓣上部署较瓣内部署使低速停滞区缩小近7倍。
核心结论
- 部署的THV几何形态可能影响血栓发生,瓣上部署的新窦可能因减少血流停滞而降低血栓风险。
研究设计与样本
- 回顾性分析RESOLVE研究中CoreValve、Evolut R和SAPIEN 3的TAVR患者术后4D容积渲染CT数据,排除抗凝患者,并辅以体外影像分析。
主要发现
- SAPIEN 3瓣叶血栓者平均直径扩张为95.5±5.2%,无血栓者为85.4±3.9%(P<0.001)。
- CoreValve/Evolut R血栓体积随植入深度线性增加(R²=0.7,P<0.001)。
- 体外分析显示瓣上部署较瓣内部署使停滞区(速度<0.1 m/s)缩小近7倍。
- 体外模型提示心输出量降低时停滞区增大。
临床怎么用
- 对于SAPIEN 3应关注瓣膜过度扩张,对于CoreValve/Evolut R应关注植入深度,以评估血栓风险。
- 瓣上部署可能减少新窦血流停滞,或有助于降低血栓风险。
局限性
- 需要进一步前瞻性研究以制定减少血栓负荷的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcatheter heart valve (THV) thrombosis has been increasingly reported. In these studies, thrombus quantification has been based on a 2-dimensional assessment of a 3-dimensional phenomenon. METHODS: Postprocedural, 4-dimensional, volume-rendered CT data of patients with CoreValve, Evolut R, and SAPIEN 3 transcatheter aortic valve replacement enrolled in the RESOLVE study (Assessment of Transcatheter and Surgical Aortic Bioprosthetic Valve Dysfunction With Multimodality Imaging and Its Treatment with Anticoagulation) were included in this analysis. Patients on anticoagulation were excluded. SAPIEN 3 and CoreValve/Evolut R patients with and without hypoattenuated leaflet thickening were included to study differences between groups. Patients were classified as having THV thrombosis if there was any evidence of hypoattenuated leaflet thickening. Anatomic and THV deployment geometries were analyzed, and thrombus volumes were computed through manual 3-dimensional reconstruction. We aimed to identify and evaluate risk factors that contribute to THV thrombosis through the combination of retrospective clinical data analysis and in vitro imaging in the space between the native and THV leaflets (neosinus). RESULTS: SAPIEN 3 valves with leaflet thrombosis were on average 10% further expanded (by diameter) than those without (95.5±5.2% versus 85.4±3.9%; P<0.001). However, this relationship was not evident with the CoreValve/Evolut R. In CoreValve/Evolut Rs with thrombosis, the thrombus volume increased linearly with implant depth (R2=0.7, P<0.001). This finding was not seen in the SAPIEN 3. The in vitro analysis showed that a supraannular THV deployment resulted in a nearly 7-fold decrease in stagnation zone size (velocities <0.1 m/s) when compared with an intraannular deployment. In addition, the in vitro model indicated that the size of the stagnation zone increased as cardiac output decreased. CONCLUSIONS: Although transcatheter aortic valve replacement thrombosis is a multifactorial process involving foreign materials, patient-specific blood chemistry, and complex flow patterns, our study indicates that deployed THV geometry may have implications on the occurrence of thrombosis. In addition, a supraannular neosinus may reduce thrombosis risk because of reduced flow stasis. Although additional prospective studies are needed to further develop strategies for minimizing thrombus burden, these results may help identify patients at higher thrombosis risk and aid in the development of next-generation devices with reduced thrombosis risk.
引用
- Midha PA, Raghav V, Sharma R, et al. The Fluid Mechanics of Transcatheter Heart Valve Leaflet Thrombosis in the Neosinus. Circulation. 2017. PMID: 28724752. doi:10.1161/CIRCULATIONAHA.117.029479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。